Cover Image
市場調查報告書

FAES Farma SA:產品平台分析

FAES Farma SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256132
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
FAES Farma SA:產品平台分析 FAES Farma SA - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 27 Pages
簡介

Faes Farma SA 致力於治療藥的研究開發及製造、行銷,不只處方藥,他們同時也製造、銷售成藥和護膚用產品。此外,也提供製藥公司原料。該公司的事業由四大結構組成,也就是專門醫藥、動物的健康和營養、醫藥品原料、以及投資活動。

本報告提供FAES Farma SA 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

FAES Farma SA的基本資料

  • FAES Farma SA概要
  • 主要資訊
  • 企業資料

FAES Farma SA:R&D概要

  • 主要的治療範圍

FAES Farma SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

FAES Farma SA:開發中產品概況

  • 最後階段有的開發中產品
    • 第三階段有的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

FAES Farma SA:藥物簡介

  • bilastine
  • Drug for Oncology
  • Drugs for Dermatitis
  • Drugs for Immunology

FAES Farma SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

FAES Farma SA:最近的開發平台趨勢

FAES Farma SA:暫停中的計劃

FAES Farma SA:企業發表

FAES Farma SA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07081CDB

Summary

Global Markets Direct's, 'FAES Farma SA - Product Pipeline Review - 2015', provides an overview of the FAES Farma SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of FAES Farma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of FAES Farma SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of FAES Farma SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the FAES Farma SA's pipeline products

Reasons to buy

  • Evaluate FAES Farma SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of FAES Farma SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the FAES Farma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of FAES Farma SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of FAES Farma SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of FAES Farma SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • FAES Farma SA Snapshot
    • FAES Farma SA Overview
    • Key Information
    • Key Facts
  • FAES Farma SA - Research and Development Overview
    • Key Therapeutic Areas
  • FAES Farma SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • FAES Farma SA - Pipeline Products Glance
    • FAES Farma SA - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • FAES Farma SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • FAES Farma SA - Drug Profiles
    • bilastine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Dermatitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Immunology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F-10503LO1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F-98214TA
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • FAES Farma SA - Pipeline Analysis
    • FAES Farma SA - Pipeline Products by Target
    • FAES Farma SA - Pipeline Products by Route of Administration
    • FAES Farma SA - Pipeline Products by Molecule Type
    • FAES Farma SA - Pipeline Products by Mechanism of Action
  • FAES Farma SA - Recent Pipeline Updates
  • FAES Farma SA - Dormant Projects
  • FAES Farma SA - Company Statement
  • FAES Farma SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • FAES Farma SA, Key Information
  • FAES Farma SA, Key Facts
  • FAES Farma SA - Pipeline by Indication, 2015
  • FAES Farma SA - Pipeline by Stage of Development, 2015
  • FAES Farma SA - Monotherapy Products in Pipeline, 2015
  • FAES Farma SA - Phase III, 2015
  • FAES Farma SA - Preclinical, 2015
  • FAES Farma SA - Pipeline by Target, 2015
  • FAES Farma SA - Pipeline by Route of Administration, 2015
  • FAES Farma SA - Pipeline by Molecule Type, 2015
  • FAES Farma SA - Pipeline Products by Mechanism of Action, 2015
  • FAES Farma SA - Recent Pipeline Updates, 2015
  • FAES Farma SA - Dormant Developmental Projects,2015
  • FAES Farma SA, Other Locations
  • FAES Farma SA, Subsidiaries

List of Figures

  • FAES Farma SA - Pipeline by Top 10 Indication, 2015
  • FAES Farma SA - Pipeline by Stage of Development, 2015
  • FAES Farma SA - Monotherapy Products in Pipeline, 2015
  • FAES Farma SA - Pipeline by Top 10 Target, 2015
  • FAES Farma SA - Pipeline by Top 10 Molecule Type, 2015
  • FAES Farma SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top